Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (131-140 of 266) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 6, 2017
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trialMiguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, et al.
European Urology|July 27, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Zoe June Assaf, Viraj Degaonkar, et al.
Obesity (Silver Spring, Md.)|August 15, 2019
Cross-Sectional, Primary Care-Based Study of the Prevalence of Hypoandrogenemia in Nondiabetic Young Men with ObesityMaría Molina-Vega, Maite Asenjo-Plaza, María Concepción García-Ruiz, et al.
Journal of Clinical Medicine|August 3, 2019
Effects of SHBG rs1799941 Polymorphism on Free Testosterone Levels and Hypogonadism Risk in Young Non-Diabetic Obese MalesDaniel Castellano-Castillo, José Luis Royo, Ana Martínez-Escribano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.
Clinical Genitourinary Cancer|August 15, 2018
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate CancerJoan Carles, Daniel Castellano, María-José Méndez-Vidal, et al.
European Urology|November 20, 2013
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancerPaweł Wiechno, Bradley G Somer, Begoña Mellado, et al.
The Journal of Clinical Endocrinology and Metabolism|February 24, 2015
Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: relationship with obesity and type 2 diabetesMercedes Clemente-Postigo, Araceli Muñoz-Garach, Marta Serrano, et al.
Cancers|July 2, 2021
Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic TherapyEmilio Esteban, Francisco Exposito, Guillermo Crespo, et al.
European Urology|February 25, 2022
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 TrialSumanta K Pal, Javier Puente, Daniel Y C Heng, et al.
Pageof 27

Showing results (131-140 of 266) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|November 6, 2017
Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trialMiguel Ángel Climent, Begoña Pérez-Valderrama, Begoña Mellado, et al.
European Urology|July 27, 2023
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial CarcinomaThomas Powles, Zoe June Assaf, Viraj Degaonkar, et al.
Obesity (Silver Spring, Md.)|August 15, 2019
Cross-Sectional, Primary Care-Based Study of the Prevalence of Hypoandrogenemia in Nondiabetic Young Men with ObesityMaría Molina-Vega, Maite Asenjo-Plaza, María Concepción García-Ruiz, et al.
Journal of Clinical Medicine|August 3, 2019
Effects of SHBG rs1799941 Polymorphism on Free Testosterone Levels and Hypogonadism Risk in Young Non-Diabetic Obese MalesDaniel Castellano-Castillo, José Luis Royo, Ana Martínez-Escribano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJacqueline Vuky, Arjun V Balar, Daniel Castellano, et al.
Clinical Genitourinary Cancer|August 15, 2018
Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate CancerJoan Carles, Daniel Castellano, María-José Méndez-Vidal, et al.
European Urology|November 20, 2013
A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancerPaweł Wiechno, Bradley G Somer, Begoña Mellado, et al.
The Journal of Clinical Endocrinology and Metabolism|February 24, 2015
Serum 25-hydroxyvitamin D and adipose tissue vitamin D receptor gene expression: relationship with obesity and type 2 diabetesMercedes Clemente-Postigo, Araceli Muñoz-Garach, Marta Serrano, et al.
Cancers|July 2, 2021
Circulating Levels of the Interferon-γ-Regulated Chemokines CXCL10/CXCL11, IL-6 and HGF Predict Outcome in Metastatic Renal Cell Carcinoma Patients Treated with Antiangiogenic TherapyEmilio Esteban, Francisco Exposito, Guillermo Crespo, et al.
European Urology|February 25, 2022
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 TrialSumanta K Pal, Javier Puente, Daniel Y C Heng, et al.
Pageof 27